Today's Radar Puts (BSEM) Front And Center (New Nasdaq Listing + Analyst Target)

It only just happened.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Today's Radar Puts (BSEM) Front And Center (New Nasdaq Listing + Analyst Target) *Get Our Updates Faster—Tap Here To Receive SMS Alerts* August 20th Greetings, Friend! It only just happened. On August 7th, shares of BioStem Technologies, Inc. (Nasdaq: BSEM) joined the Nasdaq Capital Market, closing a stretch of years quoted on OTC Markets while the company completed audited 2024 and 2025 financials and worked through exchange requirements. The listing matters less for what it says about the company than for where the company now sits. Amniotic membrane products, the category BSEM sells into, were sized at $3.6Bn globally in 2023 and are forecast to reach $8.5Bn by 2030 on a 13.1% compound rate, according to Grand View Research. Domestically, the U.S. advanced wound care market is modeled from $2.7Bn in 2022 to $4.1Bn by 2030 on a 5.43% compound rate, with the same firm citing U.S. diabetes prevalence climbing from 32.2Mn to 36.2Mn adults by 2045 as an underlying driver. Against that backdrop, BSEM reported second quarter revenue of $7.9Mn on August 12th, up roughly 29% sequentially, and raised the low end of its 2026 outlook to $26Mn from $25Mn against an unchanged $29Mn ceiling. Five weeks earlier, on July 8th, the company announced four issued U.S. design patents covering fenestrated human placental allograft technologies, part of a worldwide file it describes as exceeding 100 patents and applications. Key Company Details: BioStem Technologies, Inc. (Nasdaq: BSEM) BioStem's business is tissue processing. The company recovers donated perinatal tissue, the placental membranes available after scheduled deliveries, and converts it into allografts used in wound closure and surgical repair. Its BioRetain®, CryoTek® and SteriTek® methods are designed to preserve the tissue's structural and biological properties. Commercial output moves under the Neox®, Clarix®, VENDAJE® and American Amnion™ brands from a Pompano Beach, Florida operation accredited by the American Association of Tissue Banks and run to current Good Tissue and Good Manufacturing Practices standards. The current operating structure dates to January 21st, 2026, when BSEM acquired the surgical and wound care business of BioTissue Holdings for approximately $15Mn in cash, up to $10Mn contingent on 510(k) clearance of a new product, and up to $15Mn in commercial royalty milestones. Those lines carried roughly $29Mn of 2025 sales and brought the Neox and Clarix brands, a national sales force and the group purchasing contracts that reach hospital systems. The mix shifted accordingly: hospital sales accounted for $6.7Mn of the $7.9Mn second quarter total. Additional Sources: BSEM Website. BSEM Presentation. The August 12th Call The second quarter call reads as a sequencing document. BSEM CEO Jason Matuszewski described a period spent on internal systems, noting the company, "completed the implementation of BioStem's own customer relationship management system, and continued building the commercial organization needed to support our growth strategy." Chief Commercial Officer Barry Hassett sized the target market at roughly $26Bn across surgical and wound care applications and reiterated a year-end field target of more than 40 W-2 representatives and more than 30 independent agents, from 30 direct reps and five regional directors at the time of the call. Company CFO Brandon Poe addressed the structural margin question. The reported 61% gross margin reflects outsourced manufacturing under a transitional agreement; moving production in house could lift the blended figure by 15 to 20 percentage points. On the May call Poe noted that legacy VENDAJE products already run near 85%, and that removing the cost-plus markup alone accounts for roughly 7.5 points. We're Tracking 7 Potential Catalysts For (Nasdaq: BSEM) 1.) A Sector Compounding At 13.1% Sets The Backdrop. Grand View Research models the global amniotic membrane market from $3.6Bn in 2023 to $8.5Bn by 2030. 2.) A Float Under 15Mn Shares Means The Potential For Volatility May Be Heightened. With approximately 14.03Mn shares in its float, BSEM reads as a low float idea, which means the potential for heightened volatility may be significant. 3.) Hospital Channel Grew Approx. 24% Q2. Hospital revenue moved from $5.4Mn in the first quarter to $6.7Mn in the second, and that channel now carries roughly 85% of the BSEM top line. 4.) Guidance Floor Was Raised, Not Merely Reaffirmed. Management lifted the low end of the 2026 range to $26Mn on August 12th, which puts BSEM on a second-half pace ahead of its first half. 5.) Patent File Now Exceeds One Hundred Filings Worldwide. Four U.S. design patents on fenestrated placental allografts issued recently sit inside a portfolio BSEM describes as more than 100 patents and applications. 6.) We've Identified A $7.00 Analyst Target. H.C. Wainwright reinitiated coverage of BSEM back in May and currently maintains a $7.00 target, representing a meaningful potential upside from current levels. 7.) Demographics Support Demand Across The Cycle. U.S. diabetes prevalence is projected to rise from 32.2Mn to 36.2Mn adults by 2045, a structural driver for the wound care categories BSEM serves. Final Thought BioStem Technologies, Inc. (Nasdaq: BSEM) is not a company that has arrived. It used $5.5Mn in operations last quarter and is carrying an expense base built for a larger revenue line. What it has is a defined sector growing at a double-digit rate, a hospital footprint acquired rather than built, a dated plan to recapture margin, and a Nasdaq listing. We're initiating coverage on BioStem Technologies, Inc. (Nasdaq: BSEM). Stay tuned for updates coming soon. Talk again later. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 08/19/2026 and ending on 08/20/2026 to publicly disseminate information about (BSEM:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid forty three thousand USD ("Funds"). These Funds were part of the twenty five thousand USD funds that TD Media LLC received from a third party named Sideways Frequency LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (BSEM:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/bsem-9laoy/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Constant Contact Data Notice